• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MedImmune

MedImmune

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Evotec Enters into a Research Collaboration with Inserm in Oncology

    Evotec Enters into a Research Collaboration with Inserm in Oncology

  2. Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, With Asthma and Cystic Fibrosis Leading the Way - Research and Markets

    Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, With Asthma and Cystic Fibrosis Leading the Way - Research and Markets

  3. Virginia Bio Celebrates Women in Bio at Inaugural Conference

    Virginia Bio Celebrates Women in Bio at Inaugural Conference

  4. Benralizumab Phase III Trials Show Positive Results in Severe Asthma

    Benralizumab Phase III Trials Show Positive Results in Severe Asthma

  5. Interleukin 13 (IL13) - Pipeline Review, H1 2016 - Research and Markets

    Interleukin 13 (IL13) - Pipeline Review, H1 2016 - Research and Markets

  6. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  7. Biotech Investing for the Long Haul

    Three ways to separate long-term winners from stocks that fizzle.

  8. Morningstar Indexes: Weekly Market Report

    Week ending April 27: Quarterly earnings continue to boost market's spirits. 

  9. Services Super Sector: Major Themes

    Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.